RayStation chosen for new ultra-modern cancer center in Quebec

NewsGuard 100/100 Score

CRIC (Centre régional intégré de cancérologie) is an initiative to create a new ultra-modern cancer center in Levis, close to Quebec City. The facility will serve the Chaudière-Appalaches region. It will have the capacity to treat up to 1,700 patients per year, with the first treatments expected to take place in April 2019.

As a comprehensive cancer center, CRIC will provide services in medical oncology, radiation oncology and brachytherapy. The aim is to meet the region’s needs into the future, with a focus on using advanced technology to optimize cancer treatment. CRIC will be equipped with four Elekta Versa HD linacs, with two open vaults for future expansion, as well as the latest MR, CT and PET CT simulators.

RayStation was selected in a tender process as the sole treatment planning system for all external radiation therapy needs. Its advanced capabilities, high efficiency and capacity to integrate with the center’s treatment machines and OIS will be key factors contributing to the excellence of clinical care in the CRIC, according to the clinical leaders in the center. Adaptive therapy will be a major focus for CRIC, and RayStation’s advanced support for this treatment approach will play an essential role in the CRIC clinical workflow.

The installation will comprise many of RayStation’s advanced functionalities, including adaptive therapy, deformable registration, multi-criteria optimization, automated breast planning and biological optimization. The purchase includes 18 clinical licenses for all planners, physicists and physicians at the clinic.

Johan Löf, CEO of RaySearch, says:

CRIC has a goal of providing world-class cancer treatment, supported by the latest medical technology. With RayStation, we aim to meet the center’s needs for a future-proof treatment planning system, with the advanced features and flexibility needed to enable efficient adaptive therapy. This collaboration will result in the best possible care for many patients.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Insilico Medicine's AI-driven approach yields promising PTPN2/N1 inhibitor for cancer immunotherapy